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ABSTRACT
Introduction
It is widely recognised that stoke is a multi-factorial disorder in which platelets 
play a crucial role in thrombus formation resulting in ischaemic stroke. Platelet 
adhesion  and  aggregation  are  initiated  by  the  interaction  of  various  platelet 
glycoproteins (GP’s) such as GPIbα, which binds to von Willebrand Factor and 
GPIIb/IIIa a fibrinogen receptor. Recent studies have shown that the GP’s are 
polymorphic  and  the  polymorphisms described  within  GPIbα  such  as  Kozak-
5T/C, the variable number of tandem repeats (VNTR) and the Human Platelet 
antigen 2 (HPA2), have been implicated in the development of stroke, while the 
PIA  polymorphism of GPIIb/IIIa  was found to contribute to “aspirin resistance”. 
Therefore, these polymorphisms may be potentially important for early detection 
and early intervention and thus setting the need to provide for a high volume 
genotype testing at  health care centres.  One of the most used techniques to 
determine  platelet  function  is  platelet  aggregometry.  However,  the  major 
disadvantages of  platelet  aggregation  is  that  it  is  influenced by a  number  of 
environmental factors and its access is limited to tertiary health centres. Platelet 
aggregation measures the functional expression of platelets, which is known to 
deteriorate over time. It is for this reason that new methods at molecular level 
such as  polymerase  chain  reaction  (PCR)  are  needed to  explore  the  role  of 
genotypic  expressions,  which  are  not  influenced  by  environmental  factors. 
Currently,  conventional  PCR is  used  to  detect  platelet  polymorphisms in  the 
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research settings and has limitations as a routine diagnostic test. Furthermore, it 
is time consuming and is prone to contamination. With the recent advances in 
real-time PCR it  is possible to genotype large sample batches rapidly without 
compromising on the quality, accuracy and precision of results. This study aims 
to adapt conventional PCR methodology onto a real-time platform for detecting 
platelet  polymorphisms  that  have  been  implicated  in  both  stroke  and  aspirin 
resistance. 
Materials and methods  
A total of 60 caucasian patients classified as having ischaemic stroke by virtue of 
MRI and Doppler analysis from the Stroke Clinic at the Johannesburg Hospital 
were enrolled for this study. Healthy caucasian individuals (38), age and gender 
matched were enrolled as controls.  DNA samples were extracted from all  the 
subjects and the prevalence of the Kozak –5T/C, HPA-2, VNTR and GPIIIa PIA 
polymorphisms were determined first by using conventional PCR and then the 
real-time LightCycler TM PCR method.
Results  
The frequency of the unfavourable alleles (  the PIA2  allele for  the GPIIIa PIA 
polymorphism, the T allele for the Kozak –5T/C polymorphism, the B allele for the 
HPA-2  polymorphism  and  the  C  allele  for  the  VNTR  polymorphism)  of  the 
different GP’s were higher in the stroke patients when compared to the control 
subjects but did not reach statistical significance. There was complete statistical 
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agreement between the results obtained for the conventional PCR as compared 
to the results obtained for real-time PCR except for the VNTR polymorphism, due 
to the difficulty in designing and the unavailability of probes for the real-time PCR 
assay. However, it is important to note that adapting the real-time PCR as a new 
methodology  would  greatly  benefit  both  the  patients  and  the  clinicians  by 
providing early detection and the possibility of early therapeutic intervention.
Conclusion  
Therefore in conclusion, it is possible to perform not only conventional PCR for 
platelet  polymorphism  but  also  real-time  PCR  on  a  large  scale  without 
compromising on the quality, accuracy and precision on platelet polymorphisms 
that play a significant role in stroke and aspirin resistance. However,  a larger 
population based study needs to be performed to confirm the findings. 
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